Omeros

Yahoo Finance • 22 hours ago

Omeros, Novo Nordisk close up to $2.1B deal for phase 2 asset zaltenibart

[New Nordisk] hapabapa * Omeros (OMER [https://seekingalpha.com/symbol/OMER]) and Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) have closed a deal worth up to $2.1B for the former's phase 2 asset zaltenibart, in development f... Full story

Yahoo Finance • 23 hours ago

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

SEATTLE, December 01, 2025--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Za... Full story

Yahoo Finance • 18 days ago

Omeros Awaits FDA Decision On Lead Drug Candidate Narsoplimab Next Month

(RTTNews) - Omeros Corp. (OMER), a clinical-stage biopharmaceutical company focused on complement-mediated diseases, oncology, and addictive disorders, today announced its financial results for the third quarter ended September 30, 2025, a... Full story

Yahoo Finance • 18 days ago

Applied Therapeutics, Omeros, And Others Post Sharp Moves After Market Close

(RTTNews) - Several companies posted notable moves in after-hours trading on Thursday, driven by earnings announcements and regulatory updates. Shares of Milestone Scientific Inc. (MLSS) rose sharply in extended trading, climbing to $0.52... Full story

Yahoo Finance • 19 days ago

After-Hours Earnings Report for November 13, 2025 : AMAT, BAP, STN, GLOB, TMC, TRVI, PGEN, BZH, OMER, TBN, TOI, AIRJ

The following companies are expected to report earnings after hours on 11/13/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Applied Materials, Inc. (AMAT)is reporting for the quarter ending October 31,... Full story

Yahoo Finance • last month

Is Omeros Corporation (OMER) One of the Hot Stocks to Buy with Huge Upside Potential?

Omeros Corporation (NASDAQ:OMER) is one of the hot stocks to buy with huge upside potential. On October 15, H.C. Wainwright raised the firm’s price target on Omeros to $20 from $9 and kept a Buy rating on the shares. This sentiment followe... Full story

Yahoo Finance • last month

J.P. Morgan Maintains a Buy on Novo Nordisk (NVO)

Novo Nordisk A/S (NYSE:NVO) is one of the best long term low volatility stocks to buy right now. J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk A/S (NYSE:NVO) in a report released on October 17, setting a price... Full story

Yahoo Finance • last month

Omeros Sells Exclusive Global Rights for Drug Zaltenibart to Novo Nordisk

Omeros Corporation (NASDAQ:OMER) is one of the Reddit stocks that will go to the moon. On October 15, Omeros Corporation and Novo Nordisk (NYSE:NVO) announced a definitive asset purchase and license agreement for the clinical-stage candida... Full story

Yahoo Finance • last month

Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk and J&J in focus

U.S. stocks wavered amid increased volatility on Friday but managed to resurge, as Wall Street was rattled by concerns on the health of regional banks and credit risks while the U.S. government shutdown entered its 17th day. The benchmark... Full story

Yahoo Finance • last month

Can Novo Nordisk’s (CPSE:NOVO B) Rare Disease Deal Reshape Its Long-Term Growth Story?

Omeros Corporation recently announced it has granted Novo Nordisk exclusive global rights to develop and commercialize zaltenibart, an antibody in late-stage development for rare blood and kidney disorders, in an agreement valued at up to... Full story

Yahoo Finance • 2 months ago

Omeros Catapults 154% On A Surprise $2.1 Billion Deal With Novo Nordisk

Omeros stock catapulted Wednesday after Novo Nordisk agreed to pay up to $2.1 billion to license its experimental treatment. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks increased late Wednesday afternoon with the NYSE Health Care Index and the Health PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Top Midday Gainers

Novo Nordisk (NVO) and Omeros (OMER) struck a deal for Novo to get exclusive global rights to develo PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Omeros Catapults Almost 150% On A Surprise $2.1 Billion Deal With Novo Nordisk

Omeros stock catapulted Wednesday after Novo Nordisk agreed to pay up to $2.1 billion to license its experimental treatment. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion

Under the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Novo Nordisk, Omeros Sign Asset Purchase, License Deal for Zaltenibart

Novo Nordisk (NVO) and Omeros (OMER) said Wednesday that they have signed an asset purchase and lice PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Novo Nordisk boosts Omeros with licensing deal worth up to $2.1B

[Two coloured ropes knotting together] Richard Drury/DigitalVision via Getty Images * Omeros (NASDAQ:OMER [https://seekingalpha.com/symbol/OMER]) shares surged ~138% in the premarket on Wednesday after Novo Nordisk (NVO [https://seeking... Full story

Yahoo Finance • 2 months ago

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolioOmeros is eligible to receive 340 million US dollars in upfront and near-term milestone payments,... Full story

Yahoo Finance • 4 months ago

Omeros earnings beat by $0.03, revenue topped estimates

Investing.com - Omeros (NASDAQ: OMER) reported second quarter EPS of $-0.430, $0.03 better than the analyst estimate of $-0.460. Revenue for the quarter came in at $28.6M versus the consensus estimate of $416.67K. Omeros’s stock price clo... Full story

Yahoo Finance • 4 months ago

Earnings call transcript: Omeros beats Q2 2025 EPS forecast, stock dips

Omeros Corporation reported a better-than-expected earnings per share (EPS) for Q2 2025, with a net loss of $0.43 per share, beating the forecasted loss of $0.46. Despite this positive surprise, the company’s stock fell by 0.7% in aftermar... Full story